P2A is a short peptide sequence, originally derived from porcine teschovirus-1, that lets researchers produce two or more separate proteins from a single stretch of genetic instructions. It works by exploiting a quirk of how ribosomes read messenger RNA: instead of cutting a finished protein apart after the fact, P2A causes the ribosome to release one protein and then keep going to build the next one, all in a single pass. This trick has made P2A one of the most widely used tools in modern genetic engineering, showing up in everything from CAR-T cancer therapies to plant genome editing. But the mechanism is stranger than it sounds, the “cleavage” is not really cleavage at all, and the tool has practical quirks that anyone designing a multicistronic construct needs to understand.
How Ribosome Skipping Actually Works
When a cell reads a gene, a molecular machine called the ribosome moves along the messenger RNA, stringing amino acids together into a protein chain. Normally it keeps going until it hits a stop signal. P2A belongs to a family of short peptide sequences that hijack this process in an unusual way: they cause the ribosome to release the chain it has been building without actually stopping, and then the ribosome continues translating the next stretch of RNA into a second, separate protein. Researchers call this “ribosome skipping,” though it has also been described as “stop-carry on” or “StopGo” translation.
Early on, scientists suspected that the separation of proteins at the 2A site might involve a protease, some enzyme cutting the chain apart after it was made. That turned out to be wrong. The 2A region is not a target for any virus-encoded or host-cell protease. Instead, the effect happens during translation itself: the ribosome fails to form the normal peptide bond between the last amino acid of the 2A sequence (a proline) and the first amino acid of the downstream protein. The growing chain is released, and a new chain begins. This was recognized as a genuinely novel translational event, distinct from any previously known form of protein processing.1IntechOpen. The 2A Story: The End of the Beginning
The result is two proteins instead of one, but with small tags left behind. The upstream protein retains a short stretch of 2A-derived amino acids at its tail end, and the downstream protein starts with a proline. For many applications this residual tag is harmless, but in contexts where even a few extra amino acids matter, it becomes a design consideration worth planning around.
The Conserved Motif and What Makes P2A Tick
All functional 2A peptides share a conserved sequence at their C-terminal end. This motif is the business end of the peptide: it positions itself within the ribosome’s active site in a way that disrupts normal bond formation. Each 2A peptide represents a somewhat different structural solution for getting that conserved tail into the right spot.2Nucleic Acids Research. 2A peptides provide distinct solutions to driving stop-carry on translational recoding
But the conserved C-terminus is not the whole story. Systematic mutational studies of P2A and its relative F2A (from foot-and-mouth disease virus) have shown that residues at the N-terminal end, previously considered unimportant, also make critical contributions to skipping activity.3bioRxiv. Mapping the Functional Landscape and Viral Diversity of 2A Peptides This finding matters for anyone trying to engineer shorter or modified versions of 2A peptides: trimming the sequence too aggressively from either end can kill function.
Recent work has also uncovered distinct structural classes of 2A peptides. One class, called class B, depends on a conserved tryptophan residue at roughly position 16. Replacing that tryptophan with alanine completely abolishes skipping activity. Swapping it for phenylalanine, another bulky aromatic amino acid, partially rescues function in most cases but with an average drop of about 2.3-fold. No naturally occurring 2A peptides have been found with phenylalanine at that position, suggesting evolution has settled on tryptophan for good reason.4Cell Reports. Discovery and characterization of thousands of 2A peptides across the eukaryotic Tree of Life
Why P2A Outperforms Other 2A Peptides
P2A is not the only 2A peptide available. Four are commonly used in research: P2A (from porcine teschovirus-1), T2A (from thosea asigna virus), E2A (from equine rhinitis A virus), and F2A (from foot-and-mouth disease virus). All four produce ribosome skipping, but they do not perform equally. In side-by-side comparisons across multiple human cell lines, P2A consistently showed the highest cleavage efficiency, followed by T2A, then E2A, and finally F2A.5PLoS ONE. High Cleavage Efficiency of a 2A Peptide Derived from Porcine Teschovirus-1 in Human Cell Lines, Zebrafish and Mice This ranking held across HEK293T, HT1080, and HeLa cells, as well as in zebrafish and mouse systems, which is why P2A has become the default choice for most labs.
The practical consequence of higher skipping efficiency is that more of the protein produced downstream of P2A ends up as the intended separate product rather than as a fusion protein still attached to whatever came before. When efficiency drops, an increasing fraction of the output is a single long fusion protein that may fold incorrectly or behave unpredictably. For applications requiring precise stoichiometry between two proteins, such as making both chains of an antibody from a single construct, even modest differences in efficiency can affect yield and product quality.
P2A Versus IRES for Multi-Gene Expression
Before 2A peptides became widespread, the standard way to express multiple genes from one construct was an internal ribosome entry site, or IRES. An IRES is a stretch of RNA that recruits a second ribosome to begin translating a downstream gene independently. The two strategies solve the same problem but differ in important ways.
IRES elements typically produce less of the downstream protein relative to the upstream one, often substantially less. In a direct comparison using mouse lines engineered at the same genomic locus, constructs using the F2A peptide produced roughly six-fold more downstream protein (in this case, a fluorescent reporter) than matched IRES constructs.6PLOS ONE. Comparison of IRES and F2A-Based Locus-Specific Multicistronic Expression in Stable Mouse Lines The trade-off is that F2A also generated a significant fraction of fusion protein: about 42% of the upstream protein remained fused to the reporter, a direct consequence of incomplete ribosome skipping. P2A, with its higher cleavage efficiency, reduces this problem compared to F2A, though it does not eliminate it entirely.
Platform choice also matters more than many researchers expect. In experiments comparing P2A and IRES in DNA plasmids versus mRNA delivery, P2A generally provided stronger overall protein expression. But the picture shifted dramatically when modified nucleotides were involved. Even a modest level of modified uridine in the mRNA was enough to cripple IRES-driven expression, while P2A constructs actually showed a gradual increase in output as the fraction of modified nucleotides rose.7PubMed Central. Platform-dependent performance of P2A and IRES linkers in multicistronic gene expression Since modified mRNA is the backbone of modern mRNA therapeutics and vaccines, this finding has real implications for anyone designing multicistronic mRNA constructs: IRES may not be a reliable option in that context.
Applications in Gene Therapy and Immunotherapy
P2A has become a standard connector in the toolbox for delivering multiple therapeutic genes in a single vector. The logic is straightforward: viral vectors used in gene therapy have limited cargo capacity. If you need a patient’s cells to produce two or three proteins simultaneously, linking their genes with P2A lets you fit everything into one vector rather than needing multiple separate deliveries. The safety and effectiveness of this approach have been demonstrated in cell culture, in animal studies, and in clinical trials.8PubMed Central. Production and Application of Multicistronic Constructs for Various Human Disease Therapies
One of the highest-profile applications is in CAR-T cell therapy, where a patient’s own immune cells are engineered to recognize and attack cancer. Some CAR-T designs require multiple functional components, for instance an engineered receptor to target the tumor plus a second molecule to counteract the tumor’s immune evasion tactics. P2A provides a clean way to express both from a single construct. In one recent example, researchers linked an engineered PD1-CD28 chimeric molecule to a CAR targeting a brain tumor marker using a P2A sequence in a lentiviral vector, ensuring both components were produced in the same T cell.9PLOS ONE. PD1CD28 chimeric molecule enhances EGFRvⅢ specific CAR-T cells in xenograft experiments in mouse models
In T-cell receptor (TCR) gene therapy, P2A serves a related purpose. Engineered TCRs consist of two separate chains, alpha and beta, that must pair correctly inside the T cell. Linking the two genes with a P2A element helps ensure both chains are produced from the same cassette at balanced levels. When combined with an extra disulfide bond engineered into the TCR, this strategy can limit mispairing between the introduced chains and the cell’s own natural TCR chains, reducing the risk of unintended immune reactions.10Nature (via Journal of Investigative Dermatology / Elsevier). T-Cell Receptor Gene Therapy: Critical Parameters for Clinical Success
P2A in CRISPR and Genome Editing Workflows
Outside of therapy, P2A has become a workhorse in basic research tools built around CRISPR. A common need is to deliver both the Cas9 protein (the molecular scissors) and a selectable marker or visual reporter from the same construct. P2A makes this simple. One widely used design fuses Cas9 to a puromycin resistance gene via P2A, so that cells which successfully take up the construct can be selected by drug treatment. Researchers working with human and mouse stem cells have specifically swapped out earlier T2A linkers in favor of P2A for improved performance in these Cas9 delivery plasmids.11PLoS ONE. Highly efficient scarless knock-in of reporter genes into human and mouse pluripotent stem cells via transient antibiotic selection
In plant biology, a similar strategy has been used to build CRISPR systems in Arabidopsis, the model plant. A Cas9-P2A-GFP fusion construct allows researchers to visually track which cells express the editor by looking for green fluorescence, then identify plants that have lost the transgene in subsequent generations. P2A was chosen over other self-cleaving peptides in this system precisely because it showed the highest cleavage efficiency in plant cells.12PubMed Central. A novel CRISPR/Cas9 system for efficiently generating Cas9-free multiplex mutants in Arabidopsis
Incomplete Skipping and the Fusion Protein Problem
For all its utility, P2A does not achieve 100% ribosome skipping. Some fraction of the time, the ribosome simply reads through the 2A sequence without releasing the upstream chain, producing a single large fusion protein instead of two separate ones. The severity of this problem varies by cell type, construct design, and the specific 2A peptide used. Even with the best-performing 2A peptides, complete cleavage has not been observed in every system tested.
This incomplete skipping is especially problematic when building constructs for antibody production. In Chinese hamster ovary (CHO) cells, a standard host for manufacturing therapeutic antibodies, researchers found that none of the 2A peptides they tested achieved complete cleavage. Adding a GSG linker (a short glycine-serine-glycine sequence) immediately upstream of the 2A peptide improved efficiency and boosted antibody expression, but the uncleaved fusion products still had to be removed through purification steps to avoid incorrectly assembled antibody species and protein aggregates.13PubMed Central. Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells
For antibody production specifically, the choice and placement of signal peptides also affects how well the final antibody is secreted from the cell. Constructs that include signal peptides on both the heavy chain and light chain genes give the highest secretion levels. Removing the heavy chain signal peptide essentially eliminates antibody secretion regardless of what happens downstream, while removing the light chain signal peptide reduces secretion to a lesser degree.14PubMed. Impact of Signal Peptides on Furin-2A Mediated Monoclonal Antibody Secretion in CHO Cells These are the kinds of engineering details that can make or break a production system, and they interact with P2A function in ways that require careful optimization for each specific use case.
Stoichiometric Protein Quantification
One elegant application of 2A peptides goes beyond simply co-expressing two useful proteins. Researchers have exploited the stoichiometric nature of the skipping event, where one molecule of upstream protein is produced for every one molecule of downstream protein, to build quantitative reporters. By placing a fluorescent protein downstream of a gene of interest via a 2A linker, you can measure the brightness of the fluorescent protein and use it as a proxy for how much of the target protein is present. Studies have confirmed that this approach produces protein ratios indistinguishable from those you would get by directly fusing the two proteins together, validating it as a quantification tool in single living cells.15Cell Reports. Quantification of Protein Levels in Single Living Cells
This only works well when skipping efficiency is very high, because any uncleaved fusion product distorts the measurement. It also assumes that the 2A-derived tag left on the upstream protein does not alter its stability or turnover rate. In practice, researchers validate these assumptions for each target protein, but the approach has proven reliable enough to be used as a standard technique in several model systems.
Thousands of 2A Peptides Beyond Viruses
For years, the 2A peptide story was framed as a viral innovation: a handful of picornaviruses evolved these sequences to produce multiple proteins from compact genomes. That framing is now outdated. A large-scale search across the tree of life has identified thousands of 2A peptides in eukaryotic organisms, including insects, crustaceans, and other invertebrates, many of them functional.4Cell Reports. Discovery and characterization of thousands of 2A peptides across the eukaryotic Tree of Life These eukaryotic 2A sequences fall into distinct structural classes, some of which are quite different from the familiar viral peptides, and they expand the toolkit available for biotechnology.
The practical upshot is that researchers are no longer limited to the four classic viral 2A peptides. Newly characterized sequences with different skipping efficiencies, different residual tag lengths, or different sensitivity to cellular context could offer better solutions for specific applications. The field is still in early days of characterizing this diversity, but the sheer number of functional peptides now known suggests there is a lot of untapped potential. Some of these newly discovered 2A sequences may turn out to be better suited for particular host organisms, vector types, or therapeutic contexts than the viral peptides that have been the default for two decades.
Tunable Expression and Alternative Strategies
P2A gives roughly equal amounts of upstream and downstream protein, which is ideal when you want a one-to-one ratio. But what if you need more of one protein than another? Some research groups have developed alternative multi-gene architectures that allow tunable ratios. One approach uses leaky ribosomal scanning, where the strength of the translation initiation site in front of each gene is varied to control how much of each protein the ribosome produces. By adjusting these initiation signals, researchers can dial up or down the relative amounts of different proteins within a single construct.16Cell Systems. Tunable polycistronic expression in mammalian cells and mRNA via leaky ribosomal scanning
These tunable systems complement rather than replace P2A. In many applications, equal stoichiometry is exactly what you want, and P2A delivers it with minimal fuss. But in cases where biological function requires an excess of one component over another, for instance certain metabolic engineering pathways or signaling cascades with asymmetric requirements, having the option to move beyond a fixed one-to-one ratio is valuable. Some designs even combine P2A with these other strategies in the same construct, using P2A to link two genes at equal ratios and a different mechanism to adjust a third gene’s output independently.